Illumina, Inc.
ILMN
Market Cap$17.30B
Volume1.94M
Revenue$4.34B
Gross Profits$2.98B
Employees8970
About
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consu...
AI Summary
| Model | Near-Term (0-3 mo.) | Mid-Term (3-12 mo.) | Long-Term (1-5 yr.) |
|---|---|---|---|
| Deepseek | Hold | Buy | Buy |
| OpenAI | Buy | Hold | Buy |
| Gemini | Buy | Hold | Hold |
| Grok | Buy | Hold | Buy |
Detailed Analysis
Deepseek
Holdnear term
Current price is above the fifty-day average, indicating recent strength, but below the two-hundred-day average, suggesting longer-term caution.
Valuation:Forward PE of 22.64 suggests moderate valuation.
Technical:Price above 50-day MA but below 200-day MA, indicating mixed signals.
Sentiment:Beta of 1.326 indicates higher volatility than the market.
News:No significant recent news to drastically alter near-term outlook.
Buymid term
Potential for growth in the healthcare sector and moderate valuation could support upward movement.
Valuation:Moderate forward PE could attract investors if growth prospects improve.
Technical:If price sustains above 50-day MA, could signal strengthening trend.
Sentiment:Sector growth could improve sentiment despite volatility.
News:Anticipation of sector-specific developments could drive interest.
Buylong term
Healthcare sector's long-term growth prospects and ILMN's position within it support a positive outlook.
Valuation:Long-term growth could justify current valuation levels.
Technical:Potential to establish a stronger upward trend over time.
Sentiment:Positive sector sentiment likely to persist.
News:Innovation and expansion could drive long-term success.
Gemini
Buynear term
The stock price is above its 50-day average, suggesting positive momentum in the short term.
Valuation:Forward P/E suggests reasonable valuation.
Technical:Price above 50-day average indicates bullish trend.
Sentiment:Positive sentiment due to recent price increase.
News:Assume neutral news in the short term.
Holdmid term
The stock price is below its 200-day average, indicating potential resistance in the medium term.
Valuation:Fair valuation based on forward P/E.
Technical:Price below 200-day average suggests bearish trend.
Sentiment:Neutral sentiment due to mixed technical signals.
News:Assume neutral news in the medium term.
Holdlong term
Long-term growth prospects are uncertain, requiring further analysis of industry trends and company strategy.
Valuation:Requires deeper dive into long-term growth potential.
Technical:Long-term trend unclear based on available data.
Sentiment:Uncertain sentiment due to long-term uncertainties.
News:Requires monitoring of strategic initiatives and market positioning.
Openai
Buynear term
ILMN shows a strong recovery from its recent lows, suggesting a potential short-term upside.
Valuation:Moderately high forward PE, but potential for growth.
Technical:Price above 50-day average but below 200-day suggests short-term momentum.
Sentiment:Positive sentiment as stock recovers from lows.
News:No major negative news, stable sector outlook.
Holdmid term
While the stock shows recovery, the higher forward PE and absence of PEG ratio make mid-term prospects uncertain.
Valuation:Forward PE is high; growth needs to justify this valuation.
Technical:Needs to breach 200-day average to confirm longer bullish trend.
Sentiment:Mixed sentiment, dependent on broader market and sector performance.
News:Dependent on forthcoming financial results and sector trends.
Buylong term
Long-term growth potential in healthcare sector and technological advancements may benefit ILMN.
Valuation:Assuming growth, current valuation could become attractive.
Technical:Long-term technicals will depend on maintaining upward momentum.
Sentiment:Healthcare innovation could drive positive long-term sentiment.
News:Future innovation and market expansion could be key drivers.
Grok
Buynear term
Current price above 50-day average signals short-term strength. Momentum may continue with positive sentiment.
Valuation:Forward P/E of 22.64 suggests reasonable valuation.
Technical:Price above 50-day average indicates bullish momentum.
Sentiment:Market sentiment appears cautiously optimistic.
News:No major negative news; stable outlook.
Holdmid term
Price below 200-day average suggests potential resistance. Balanced risk-reward with limited catalysts.
Valuation:Forward P/E reasonable but lacks growth clarity.
Technical:Below 200-day average; possible consolidation phase.
Sentiment:Neutral sentiment with mixed analyst views.
News:Limited impactful news expected in mid-term.
Buylong term
Healthcare sector growth and innovation favor ILMN. Long-term potential outweighs current volatility.
Valuation:Current valuation attractive for long-term growth.
Technical:Long-term trends less relevant; fundamentals key.
Sentiment:Positive long-term outlook in genomics sector.
News:Potential for innovation-driven positive developments.